Skip to main content

Table 2 Effect of umbelliferone β-D-galactopyranoside on blood glucose levels in oral glucose tolerance test in normoglycemic rats

From: Umbelliferone β-D-galactopyranoside from Aegle marmelos (L.) corr. an ethnomedicinal plant with antidiabetic, antihyperlipidemic and antioxidative activity

S. No. Treatment Dose Mean blood glucose concentration ± SEM (mg/dl)
    Time 0 min Time 30 min Time 60 min Time 120 min
1 Normal Control - 87.2 ± 0.837 87.2 ± 0.834 87.8 ± 0.735 87.8 ± 0.583
2 Normal Control + UFG 40 mg/kg 86.8 ± 0.735 86.4 ± 0.734 84.4 ± 0.245 80.8 ± 0.583
3 Glucose Control - 88.8 ± 0.861 140.4 ± 2.315 135 ± 1.143 129 ± 1.963
4 UFG I 10 mg/kg 88.4 ± 0.734 139.4 ± 1.158ns 127.8 ± 1.021* 106 ± 1.145***
5 UFG II 20 mg/kg 87.4 ± 1.077 130 ± 1.158* 116.6 ± 1.435** 101.4 ± 1.032***
6 UFG III 40 mg/kg 88.8 ± 0.734 124.8 ± 1.497** 109 ± 0.732*** 87 ± 1.789***
7 Glibenclamide 10 mg/kg 89 ± 0.707 125 ± 1.068** 111.4 ± 1.034*** 88.6 ± 1.568***
  1. All values represent mean ± SEM * P < 0.05; ** P < 0.01; *** P < 0.001, ns < non significant; ANOVA, followed by Dunnett’s multiple comparison test.